GPR120 regulation of intestinal IgA responses and gut IgA-coated bacteria
GPR120 对肠道 IgA 反应和肠道 IgA 包被细菌的调节
基本信息
- 批准号:10176396
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:16S ribosomal RNA sequencingAgonistAntibodiesB-LymphocytesBacteriaBindingCell physiologyColitisDataDiabetes MellitusDietDietary ComponentDietary FatsDietary Fatty AcidDiseaseEnergy-Generating ResourcesG-Protein-Coupled ReceptorsGene ExpressionGene Expression ProfileHomeostasisImmuneImmune responseImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin Switch RecombinationIn VitroInflammationInflammatoryInflammatory Bowel DiseasesInsulin ResistanceIntestinal MucosaIntestinesKnowledgeMediatingMetabolic DiseasesMolecularMucous MembraneMusNonesterified Fatty AcidsNutrientObesityPathogenesisPathway interactionsPatientsPlayProductionRegulationRoleSecretory Immunoglobulin ASignaling MoleculeSurfaceT-LymphocyteTestingTransforming Growth Factor betaautocrinecytokinedietaryfeedinggut bacteriagut microbiotainflammatory disease of the intestineintestinal homeostasislipid biosynthesislong chain fatty acidmagnetic cell separationmicrobiotanew therapeutic targetnovelpreservationreceptorresponsetherapeutic target
项目摘要
Abstract
Increasing evidence suggests that the interactions between diet and the gut microbiota may play a critical role
in promoting or alleviating intestinal inflammation. However, little is known about the mechanisms involved. Free
fatty acids provide important energy sources as dietary nutrients, and act as signaling molecules in various
cellular processes. Most notable among the free fatty acids targets are mammalian G protein-coupled receptors
(GPR). GPR120 (also known as free fatty acid receptor 4, FFAR4) has been identified as a bona fide receptor
for long-chain fatty acids (LCFA) from dietary products and has a critical role in various physiological homeostasis
mechanisms such as adipogenesis. Its agonists are suggested as therapeutic targets for diabetes, metabolic
disorders, and inflammatory diseases. However, the mechanisms involved are still largely unknown. Intestinal
mucosal surfaces are protected by a first-line defense mediated by secretory Immunoglobulin A (SIgA), which
has been shown to be critical in mucosal immune defense. Intestinal IgA can be produced by both T cell-
dependent and T cell-independent pathways, however, the relative importance of each and how they are
regulated are still largely unclear. Although both are enriched in the intestines, there is a significant knowledge
gap regarding how LCFA regulate intestinal IgA responses as well as the role of the LCFA-IgA axis in the
regulation of host responses to microbiota and intestinal homeostasis. In this application, we will test the
hypothesis that GPR120 promotes intestinal IgA responses to microbiota through either substituting for TGFβ,
which is a critical cytokine in induction of B cell production of IgA, or through promoting TGFβ production by B
cells to enhance IgA production, leading to the preservation of intestinal immune homeostasis by regulating the
function and composition of gut microbiota. Aim 1 will define the molecular mechanisms by which GPR120
promotes intestinal IgA responses, and Aim 2 will determine whether GPR120-mediated intestinal production of
IgA alters gut microbiota to contribute to intestinal homeostasis. If successful, this project will potentially provide
a novel therapeutic target for treatment of patients with inflammatory bowel disease.
摘要
越来越多的证据表明,饮食和肠道微生物群之间的相互作用可能起着关键作用
促进或减轻肠道炎症。然而,人们对所涉及的机制知之甚少。免费
脂肪酸作为膳食营养素提供重要的能量来源,并在各种疾病中充当信号分子。
细胞过程在游离脂肪酸靶点中最值得注意的是哺乳动物G蛋白偶联受体
(GPR)。GPR 120(也称为游离脂肪酸受体4,FFAR 4)已被鉴定为真正的受体
长链脂肪酸(LCFA)的膳食产品,并在各种生理稳态的关键作用
脂肪生成等机制。它的激动剂被建议作为糖尿病、代谢性疾病和糖尿病的治疗靶点。
疾病和炎性疾病。然而,所涉及的机制在很大程度上仍然是未知的。肠
粘膜表面受到分泌型免疫球蛋白A(SIgA)介导的第一线防御的保护,
已经显示在粘膜免疫防御中是关键的。肠道伊加可以由T细胞和淋巴细胞产生。
依赖性和T细胞非依赖性途径,然而,每一个的相对重要性,以及它们是如何
监管在很大程度上仍不明确。虽然两者都是在肠道中富集,但有一个重要的知识
关于LCFA如何调节肠道伊加反应以及LCFA-IgA轴在肠道免疫反应中的作用,
调节宿主对微生物群和肠道内稳态的反应。在本应用程序中,我们将测试
假设GPR 120通过替代TGFβ,
其是诱导B细胞产生伊加或通过促进B细胞产生TGFβ的关键细胞因子
细胞,以提高伊加的生产,从而导致肠道免疫稳态的保护,通过调节
肠道微生物群的功能和组成。目的1将定义GPR 120
促进肠道伊加应答,Aim 2将确定GPR 120介导的肠道IgA产生是否
伊加改变肠道微生物群以促进肠道内稳态。如果成功,该项目将提供
用于治疗炎症性肠病患者的新治疗靶点。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells.
- DOI:10.1096/fj.202001524r
- 发表时间:2020-11
- 期刊:
- 影响因子:0
- 作者:Yu Y;Yang W;Bilotta AJ;Yu Y;Zhao X;Zhou Z;Yao S;Xu J;Zhou J;Dann SM;Li Y;Cong Y
- 通讯作者:Cong Y
The disruption of intestinal homeostasis when foods are colored red.
当食物呈红色时,肠道稳态会受到破坏。
- DOI:10.1038/s41423-022-00875-0
- 发表时间:2022
- 期刊:
- 影响因子:24.1
- 作者:Yang,Wenjing;Cong,Yingzi
- 通讯作者:Cong,Yingzi
GPR120 promotes neutrophil control of intestinal bacterial infection.
- DOI:10.1080/19490976.2023.2190311
- 发表时间:2023-01
- 期刊:
- 影响因子:12.2
- 作者:
- 通讯作者:
Th17 Cell-Derived Amphiregulin Promotes Colitis-Associated Intestinal Fibrosis Through Activation of mTOR and MEK in Intestinal Myofibroblasts.
Th17 细胞衍生的双调蛋白通过激活肠肌成纤维细胞中的 mTOR 和 MEK 促进结肠炎相关的肠纤维化。
- DOI:10.1053/j.gastro.2022.09.006
- 发表时间:2023
- 期刊:
- 影响因子:29.4
- 作者:Zhao,Xiaojing;Yang,Wenjing;Yu,Tianming;Yu,Yu;Cui,Xiufang;Zhou,Zheng;Yang,Hui;Yu,Yanbo;Bilotta,AnthonyJ;Yao,Suxia;Xu,Jimin;Zhou,Jia;Yochum,GregoryS;Koltun,WalterA;Portolese,Austin;Zeng,Defu;Xie,Jingwu;Pinchuk,IrynaV;
- 通讯作者:
IL-21 Promotes Intestinal Memory IgA Responses.
- DOI:10.4049/jimmunol.1900766
- 发表时间:2020-10-01
- 期刊:
- 影响因子:0
- 作者:Huang X;Yang W;Yao S;Bilotta AJ;Lu Y;Zhou Z;Kumar P;Dann SM;Cong Y
- 通讯作者:Cong Y
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JIAREN SUN其他文献
JIAREN SUN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JIAREN SUN', 18)}}的其他基金
Retinoic Acid Regulates S100 Proteins and Immune Responses in Viral Hepatitis
视黄酸调节病毒性肝炎中的 S100 蛋白和免疫反应
- 批准号:
9169284 - 财政年份:2016
- 资助金额:
$ 19.75万 - 项目类别:
Damage-associated Alarmin Key to Immune Responses in Viral Hepatitis
损伤相关警报蛋白是病毒性肝炎免疫反应的关键
- 批准号:
8771220 - 财政年份:2014
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
7759108 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
8212128 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
7556368 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
8019445 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
7207478 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Mechanisms of HCV Persistence and Pathogenesis
HCV 持续存在和发病机制的免疫机制
- 批准号:
7342863 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Immune Costimulatory Molecules in HCV Pathogenesis
HCV 发病机制中的免疫共刺激分子
- 批准号:
6741223 - 财政年份:2003
- 资助金额:
$ 19.75万 - 项目类别:
Immune Costimulatory Molecules in HCV Pathogenesis
HCV 发病机制中的免疫共刺激分子
- 批准号:
6804734 - 财政年份:2003
- 资助金额:
$ 19.75万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 19.75万 - 项目类别:














{{item.name}}会员




